echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > FDA Issues Complete Response Letter (CRL) for Somatrogon for Growth Hormone Deficiency (GHD)

    FDA Issues Complete Response Letter (CRL) for Somatrogon for Growth Hormone Deficiency (GHD)

    • Last Update: 2022-02-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Pfizer and its partner OPKO Health today announced that the FDA has issued a Complete Response Letter (CRL) for Somatrogon, an investigational once-weekly growth hormone deficiency (GHD) therapy
    .

    FDA

    Growth hormone deficiency (GHD) is a rare but treatable growth disorder in children
    that can occur alone or in combination with other anterior and/or posterior pituitary hormone deficiencies .


    In 2020, the prevalence of GHD diagnoses in seven major markets (US, France, Germany, Spain, Italy, UK and Japan) was only 0.


    Diagnosis of children

    For decades, the standard of care for GHD has been daily injections of recombinant human GH, although this regimen has been associated with poor adherence to treatment and poor treatment outcomes
    .


    This has prompted drug developers to invest in the development of long-acting GH formulations that require less frequent dosing


    The application was supported by a Phase III trial that enrolled a total of 224 subjects randomized 1:1 to receive either weekly Somatrogon hGH-CTP (0.
    66 mg/kg) or once-daily Genotropin (0.
    24 mg/kg) mg/kg/wk) for 12 months
    .


    The primary endpoint of the study was height velocity (HV) at 12 months


    First-line results from the pivotal Phase III trial showed that weekly Somatrogon (hGH-CTP) administered subcutaneously was non-inferior to once-daily Genotropin (hGH)
    .

    First-line results from the pivotal Phase III trial showed that weekly Somatrogon (hGH-CTP) administered subcutaneously was non-inferior to once-daily Genotropin (hGH)
    .


    First-line results from the pivotal Phase III trial showed that weekly Somatrogon (hGH-CTP) administered subcutaneously was non-inferior to once-daily Genotropin (hGH)


    Original source:

    Original source:

    https://firstwordpharma.


    https://firstwordpharma.
    com/story/5485151 https://firstwordpharma.
    com/story/5485151 Leave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.